Psychometric characteristics of the italian version of the revised fibromyalgia impact questionnaire using classical test theory and rasch analysis

Clinical and Experimental Rheumatology

Volumn 31, Issue SUPPL.79, 2013, Pages 41-49

  Salaffi, Fausto ^a   Franchignoni, Franco ^b   Giordano, Andrea ^b   Ciapetti, Alessandro ^a   Sarzi Puttini, Piercarlo ^c   Ottonello, Marcella ^b  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b IRCCS   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Classical test theory; Fibromyalgia; Fibromyalgia impact questionnaire revised version; Psychometrics; Rasch analysis

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL EVALUATION; DISEASE DURATION; FEMALE; FIBROMYALGIA; FIBROMYALGIA IMPACT QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOMETRY; RELIABILITY; SCORING SYSTEM; SENSITIVITY ANALYSIS; SYMPTOM; VALIDITY;

EID: 84892451328     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. WOLFE F, ROSS K, ANDERSON J, RUSSELL IJ, HEBERT L: The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995; 38: 19-28.
2. MEASE P: Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol 2005; 32 (Suppl. 75): 6-21.
3. SALAFFI F, SARZI-PUTTINI P: Old and new criteria for the classification and diagnosis of fibromyalgia: comparison and evaluation. Clin Exp Rheumatol 2012; 30 (Suppl. 74): S3-9.
4. SALAFFI F, DE ANGELIS R, GRASSI W; marche Pain Prevalence, Investigation Group (MA PPING ) study: Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community- based study. I. The MAPPING study. Clin Exp Rheumatol 2005; 23: 819-28.
5. MAS AJ, CARMONA L. M. VALVERDE M, RIBAS B, and the EPISER Study Group: Prevalence and impact of ?bromyalgia on function and quality of life in individuals from the general population: results from a nationwide study in Spain. Clin Exp Rheumatol 2008; 26: 519-26.
6. SALAFFI F, SARZI-PUTTINI P, GIROLIMETTI R, ATZENI F, GASPARINI S, GRASSI W: Health-related quality of life in fibromyalgia patients: a comparison with rheumatoid arthritis patients and the general population using the SF-36 health survey. Clin Exp Rheumatol 2009; 27 (Suppl. 56): S67-74.
7. KIVIMäKI M, LEINO-ARJAS P, KAILA-KANGAS L et al.: Increased absence due to sickness among employees with fibromyalgia. Ann Rheum Dis 2007; 66: 65-9.
8. CALANDRE EP, VILCHEZ JS, MOLINA-BAREA R et al.: Suicide attempts and risk of suicide in patients with fibromyalgia: a survey in Spanish patients. Rheumatology (Oxford) 2011; 50: 1889-93.
9. OFLUOGLU D, BERKER N, GüVEN Z, CANBULAT N, YILMAZ IT, KAYHAN O: Quality of life in patients with fibromyalgia syndrome and rheumatoid arthritis. Clin Rheumatol 2005; 24: 490-2.
10. HAWLEY DJ, WOLFE F: Pain, disability, and pain/disability relationships in seven rheumatic disorders: a study of 1,522 patients. J Rheumatol 1991; 18: 1552-7.
11. SALAFFI F, CAROTTI M, GASPARINI S, INTORCIA M, GRASSI W: The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people. Health Qual Life Outcomes 2009; 18: 7-25.
12. YILMAZ F, SAHIN F, ERGOZ E et al.: Quality of life assessments with SF 36 in different musculoskeletal diseases. Clin Rheumatol 2008; 27: 327-32.
13. HOFFMAN DL, DUKES EM: The health status burden of people with fibromyalgia: a review of studies that assessed health status with the SF-36 or the SF-12. Int J Clin Pract 2008; 62: 115-26.
14. LOZA E, ABáSOLO L, JOVER JA, CARMONA L, EPISER Study Group: Burden of disease across chronic diseases: a health survey that measured prevalence, function, and quality of life. J Rheumatol 2008; 35: 159-65.
15. DWORKIN RH, TURK DC, WYRWICH KW et al.: Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008: 9: 105-21.
16. BASCH E: Beyond the FDA PRO guidance: steps toward integrating meaningful patientreported outcomes into regulatory trials and US drug labels. Value Health 2012; 15: 401- 3.
17. TESTA MA, SIMONSON DC: Assessment of quality-of-life outcomes. N Engl J Med 1996; 28: 835-40.
18. SALAFFI F, SARZI-PUTTINI P, CIAPETTI A, ATZENI F: Assessment instruments for patients with fibromyalgia: properties, applications and interpretation. Clin Exp Rheumatol 2009; 27 (Suppl. 56): S92-105.
19. BURCKHARDT CS, CLARK SR, BENNETT RM: The Fibromyalgia Impact Questionnaire: development and validation. J Rheumatol 1991; 18: 728-33.
20. BENNETT RM, FRIEND R, JONES KD, WARD R, HAN BK, ROSS RL: The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties. Arthritis Res Ther 2009; 11: R120.
21. DUNKL PR, TAYLOR AG, McCONNELL GG, ALFANO AP, CONAWAY MR: Responsiveness of fibromyalgia clinical trial outcome measures. J Rheumatol 2000; 27: 2683-91.
22. BENNETT R: The Fibromyalgia Impact Questionnaire (FIQ): a review of its development, current version, operating characteristics and uses. Clin Exp Rheumatol 2005; 23 (Suppl. 39): S154-S162.
23. BOOMERSHINE CS: A comprehensive evaluation of standardized assessment tools in the diagnosis of fibromyalgia and in the assessment of fibromyalgia severity. Pain Res Treat 2012; 2012: 653-714.
24. SRIFI N, BAHIRI R, ROSTOM S, BENDEDDOUCHE I, LAZREK N, HAJJAJ-HASSOUNI N: The validity and reliability of the Moroccan version of the Revised Fibromyalgia Impact Questionnaire. Rheumatol Int 2013; 33: 179- 83.
25. EDIZ L, HIZ O, TOPRAK M, TEKEOGLU I, ERCAN S: The validity and reliability of the Turkish version of the Revised Fibromyalgia Impact Questionnaire. Clin Rheumatol 2011; 30: 339-46.
26. WOLFE F, SMYTHE HA, YUNUS MB et al.: The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33: 160-72.
27. SALAFFI F, SARZI-PUTTINI P, GIROLIMETTI R, GASPARINI S, ATZENI F, GRASSI W: Development and validation of the self-administered Fibromyalgia Assessment Status: a disease-specific composite measure for evaluating treatment effect. Arthritis Res Ther 2009; 11: R125.
28. IANNUCCELLI C, SARZI-PUTTINI P, ATZENI F et al.: Psychometric properties of the Fibromyalgia Assessment Status (FAS) index: a national web-based study of fibromyalgia. Clin Exp Rheumatol 2011; 29 (Suppl. 69): S49-54.
29. GUILLEMIN F, BOMBARDIER C, BEATON D: Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol 1993; 46: 1417-32.
30. SALAFFI F, CIAPETTI A, SARZI-PUTTINI P et al.: Preliminary identification of key clinical domains for outcome evaluation in fibromyalgia using the Delphi method: the Italian experience. Reumatismo 2012; 19: 27-34.
31. STREINER DL, NORMAN GR: Health measurement scales. A practical guide to their development and use. 2nd ed., Oxford, Oxford University Press, 1995: 163-80.
32. HORN JL: A rationale and test for the number of factors in factor analysis. Psychometrika 1965; 30: 179-85.
33. JöRESKOG KG: Structural Equation Modeling with Ordinal Variables using LISREL. Scientific Software International: Lincolnwood, IL 2005. Available at: http://www. ssicentral.com/lisrel/techdocs/ordinal.pdf. Accessed July 20, 2012.
34. GUADAGNOLI E, VELICER WF: Relation of sample size to the stability of component patterns. Psychol Bull 1988; 103: 265-75.
35. HU LT, BENTLER PM: Cut-off criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives. Struct Equ Modeling 1999; 6: 1-55.
36. LINACRE JM: A user's guide to Winsteps- Ministep: Rasch-model computer programs. Program manual 3.68.0. Chicago, IL: WINSPTEPS. com; 2009. Available at: http//winsteps. com/a/winsteps.htm. Accessed February 15, 2010.
37. BOND TG, FOX CM: Applying the Rasch model: fundamental measurement in the human sciences. Mahwah, Lawrence Erlbaum Associates, 2001: 158-86.
38. FRANCHIGNONI F, GIORDANO A, SARTORIO F, VERCELLI S, PASCARIELLO B, FERRIERO G: Suggestions for refinement of the Disabilities of the Arm, Shoulder and Hand Outcome Measure (DASH): a factor analysis and Rasch validation study. Arch Phys Med Rehabil 2010; 91: 1370-7.
39. LINACRE JM: Optimizing rating scale category effectiveness. J Appl Meas 2002; 3: 85-106.
40. FROST MH, REEVE BB, LIEPA AM, STAUFFER JW, HAYS RD, Mayo/FDA Patient-Reported Outcomes Consensus Meeting Group: What is sufficient evidence for the reliability and validity of patient-reported outcome measures? Value Health 2007; 10 (Suppl. 2): S94- 105.
41. MEASE P, ARNOLD LM, CHOY EH et al.: OMERACT Fibromyalgia Working Group. Fibromyalgia syndrome module at OMERACT 9: domain construct. J Rheumatol 2009; 36: 2318-29.
42. VELICER WF, FAVA JL: Effects of variable and subject sampling on factor pattern recovery. Psychol Methods 1998; 3: 231-51.
43. FRANCHIGNONI F, GIORDANO A, FERRIERO G, ORLANDINI D, AMORESANO A, PERUCCA L: Measuring mobility in people with lower limb amputation: Rasch analysis of the mobility section of the prosthesis evaluation questionnaire. J Rehabil Med 2007; 39: 138- 44.
44. KHADKA J, GOTHWAL VK, McALINDEN C, LAMOUREUX EL, PESUDOVS K: The importance of rating scales in measuring patientreported outcomes. Health Qual Life Outcomes 2012, 10: 80.
45. SARZI-PUTTINI P, ATZENI F, DI FRANCO M et al.: Dysfunctional syndromes and fibromyalgia: a 2012 critical digest. Clin Exp Rheumatol 2012; 30 (Suppl. 74): S143-51.
46. ALCIATI A, SARZI-PUTTINI P, BATTICCIOTTO A et al.: Overactive lifestyle in patients with fibromyalgia as a core feature of bipolar spectrum disorder. Clin Exp Rheumatol 2012; 30 (Suppl. 74): S122-8.
47. DöNMEZ S, PAMUK öN, üMIT EG, TOP MS: Autoimmune rheumatic disease associated symptoms in fibromyalgia patients and their influence on anxiety, depression and somatisation: a comparative study. Clin Exp Rheumatol 2012; 30 (Suppl. 74): S65-9.